QuantHealth closes $45M Series B for AI clinical trial simulation
QuantHealth, a Tel Aviv company building AI software to simulate clinical trials, has closed a $45 million Series B round led by Qumra Capital, according to reporting aggregated by Techmeme and attributed to Cailey Gleeson at Fierce Healthcare. The financing lifts the startup's total funding to roughly $70 million and marks a sizable bet on tools that aim to reduce the cost and duration risks of pharmaceutical research and development. Investor appetite for specialized clinical-trial infrastructure suggests simulation is moving from experimental analytics toward commercially validated enterprise software. The round lends credibility to platforms that use historical trial data to model outcomes before costly human studies begin. Operators should note the available reporting emphasizes financing totals rather than disclosed adoption or revenue metrics.
QuantHealth closes $45M Series B for AI clinical trial simulation
Tel Aviv-based QuantHealth, a provider of AI clinical trial simulation software, raised a $45M Series B led by Qumra Capital, taking its total funding to ~$70M.
Key takeaway
Venture capital is backing AI clinical trial simulation as infrastructure to offset the time and cost pressures of pharmaceutical R&D pipelines.
What happened
Tel Aviv-based QuantHealth, a provider of AI clinical trial simulation software, raised a $45M Series B led by Qumra Capital, taking its total funding to approximately $70M, according to Techmeme reporting attributed to Cailey Gleeson at Fierce Healthcare.
The Series B was led by Qumra Capital, and the round positions QuantHealth among vendors offering AI-driven simulation intended to de-risk and accelerate clinical trial planning using historical trial data.
Evidence
QuantHealth raised a $45M Series B led by Qumra Capital, bringing total funding to about $70M.
Techmeme · attributed
Tel Aviv-based QuantHealth, a provider of AI clinical trial simulation software, raised a $45M Series B led by Qumra Capital, taking its total funding to ~$70M.
The funding was reported by Cailey Gleeson at Fierce Healthcare via Techmeme.
Techmeme · attributed
Cailey Gleeson / Fierce Healthcare : Tel Aviv-based QuantHealth, a provider of AI clinical trial simulation software, raised a $45M Series B led by Qumra Capital, taking its total funding to ~$70M
The round signals investor confidence in AI simulation to de-risk and accelerate clinical trial outcomes.
Techmeme · attributed
QuantHealth's $45M Series B signals sustained investor confidence in AI-driven simulation as a mechanism to de-risk and accelerate clinical trial outcomes.
The investment is framed as validation of commercial viability for AI clinical trial simulation software leveraging historical data.
Techmeme · attributed
Tel Aviv-based QuantHealth secured $45M in Series B funding led by Qumra Capital, bringing its total capitalization to approximately $70M. This investment validates the commercial viability of AI clinical trial simulation software, which leverages historical
Why it matters
A Series B at this scale signals that trial simulation vendors may compete for pharma partnerships and enterprise budgets beyond early pilots.
Limits and uncertainties
Available excerpts are truncated and do not disclose customer adoption, revenue, or clinical validation outcomes.
Reporting is aggregated through Techmeme; no direct Fierce Healthcare article URL is included in the evidence packet.
Practical implications
Digital health builders should track clinical trial simulation vendors as potential partners or acquisition targets as capital concentrates in the category.
Pharma R&D teams may see increased vendor outreach tied to trial de-risking and timeline compression narratives.
What to watch
Follow-on Fierce Healthcare reporting on QuantHealth customers, use cases, and pharma partnerships.
Whether comparable funding rounds emerge at rival AI clinical trial simulation vendors.
Original reporting: Tel Aviv-based QuantHealth, a provider of AI clinical trial simulation software, raised a $45M Series B led by Qumra Capital, taking its total funding to ~$70M (Cailey Gleeson/Fie…
